Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|January 5, 2021

BioPharm International Sponsored eBooks

  • BioPharm International Sponsored eBooks-01-06-2021
  • Issue 1

Characterizing Vaccines with the Light Scattering Toolkit

This paper includes a brief introduction to light scattering instruments and techniques, and how they are coupled with fractionation techniques. For several classes of vaccines – including subunit vaccines, mRNA-LNPs, polysaccharide conjugates, and plain old viruses – case studies demonstrate the utility and breadth of analyses using the light scattering toolkit. These include measuring size distributions, characterizing protein-protein binding, and quantifying glycan content in glycoproteins or nucleic acid cargo in nanocarriers. Multiple ways to detect aggregation and other measures of stability are also described.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.